CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $74,000 | -92.8% | 1,224 | -86.7% | 0.01% | -92.7% |
| Q3 2021 | $1,032,000 | +339.1% | 9,218 | +534.0% | 0.12% | +342.9% |
| Q2 2021 | $235,000 | +13.0% | 1,454 | -14.9% | 0.03% | 0.0% |
| Q1 2021 | $208,000 | -63.5% | 1,709 | -54.1% | 0.03% | -65.0% |
| Q4 2020 | $570,000 | +102.1% | 3,722 | +10.5% | 0.08% | +77.8% |
| Q3 2020 | $282,000 | -56.9% | 3,369 | -62.2% | 0.04% | -60.2% |
| Q2 2020 | $655,000 | +2325.9% | 8,913 | +1077.4% | 0.11% | +2160.0% |
| Q1 2019 | $27,000 | +35.0% | 757 | +10.0% | 0.01% | +25.0% |
| Q4 2018 | $20,000 | -51.2% | 688 | -25.9% | 0.00% | -42.9% |
| Q3 2018 | $41,000 | -74.4% | 928 | -66.0% | 0.01% | -75.9% |
| Q2 2018 | $160,000 | +290.2% | 2,726 | +202.9% | 0.03% | +262.5% |
| Q1 2018 | $41,000 | – | 900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |